Wilmington, New Castle, Delaware, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Cancer Supportive Care Drugs Market By Type (Erythropoiesis Stimulating Agents, Granulocyte Colony Stimulating Factors, Antiemetics, Bisphosphonates, Opioids, Nonsteroidal Anti Inflammatory Drugs, and Others), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032”. According to the report, the global cancer supportive drugs market was valued at $20.3 billion in 2022 and is projected to reach $24.9 billion by 2032, registering a CAGR of 2.03% from 2023 to 2032.
Prime Determinants of Growth
Growth in healthcare infrastructure, rise in the number of cancer cases and growth in awareness regarding the use of cancer supportive drugs are the factors that drive the growth of the global cancer supportive drugs market. However, advancements in targeted therapy for cancer hinder the market growth. On the contrary, a rise in healthcare expansion is expected to offer remunerative opportunities for the cancer supportive drugs market during the forecast period.
Request Sample of the Report on Cancer Supportive Care Drugs Market Forecast 2032: https://www.alliedmarketresearch.com/request-sample/A07133
Report Coverage & Details:
| Report Coverage | Details |
| Forecast Period | 2023–2032 |
| Base Year | 2022 |
| Market Size In 2022 | $20.3 Billion |
| Market Size In 2032 | $24.9 Billion |
| CAGR | 2.03% |
| No. Of Pages In Report | 334 |
| Segments Covered | Type, Application, Distribution Channel, And Region |
| Drivers | Rise In Prevalence Of Cancer And Adverse Effects Associated With Use Of Cancer Drugs. |
| Increase In Adoption Of Cancer Supportive Care Drugs. | |
| Growth In Geriatric Population. | |
| Opportunities | Increase In R&D And Number Of Pipeline Cancer Supportive Care Drugs. |
| Restraints | Advancements In Targeted Therapy For Cancer |
Recession Scenario
- During a recession, the impact on the healthcare industry, including cancer supportive drugs, can be significant.
- The economic downturns may hinder research and development investment. However, the growing number of cancer cases and the rising focus on post-cancer treatment care can drive interest in cancer supportive drugs.
Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A07133
The granulocyte colony-stimulating factors segment maintained its lead position during the forecast period.
By type, the granulocyte colony-stimulating factors segment dominated the market in 2022, accounting for more than one-third of the global cancer supportive drugs market This is attributed to G-CSFs playing a crucial role in supporting cancer patients by stimulating the production of white blood cells, thereby aiding in the prevention of infections during chemotherapy. This vital function has positioned G-CSFs as a primary choice in cancer supportive care, driving their market share and revenue. However, the antiemetics segment is expected to register the fastest CAGR of 3.03% during the forecast period. Antiemetics significantly enhances the quality of life for patients undergoing chemotherapy. The rising demand for effective nausea and vomiting control is expected to drive the rapid growth of the antiemetics segment in the cancer supportive care drugs market.
The breast cancer segment is expected to maintain its lead position during the forecast period.
By application, the breast cancer segment dominated the market in 2022, accounting for more than one-fifth of the global cancer supportive drugs market. The surge in breast cancer prevalence and increased adoption of diverse treatments, often accompanied by side effects, contribute to a rising demand for cancer supportive care drugs. This sustained need positions the breast cancer segment as a significant driver of market revenue. However, the lung cancer segment is expected to register the fastest CAGR of 2.67% during the forecast period owing to a surge in lung cancer cases, intensifying the demand for supportive care interventions. As awareness about the importance of comprehensive and effective supportive care grows and treatment options expand, there is an imperative need to address the unique challenges associated with lung cancer. This drive is essential for enhancing the overall quality of life for individuals affected by lung cancer, emphasizing the critical role of supportive care in managing the complexities of the disease and its treatments.
The drug stores & retail pharmacies segment maintained its lead position during the forecast period.
By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022, accounting for almost half of the global cancer supportive drugs market, owing to several factors, including convenience, accessibility, and the widespread presence of drug stores and retail pharmacies. Additionally, the familiarity of patients with these establishments, along with the availability of over-the-counter supportive care products, contributes to the segment's revenue dominance. However, the online providers segment is expected to register the fastest CAGR of 2.05% during the forecast period. This is primarily due to the convenience, accessibility, and ability to reach a broader audience through digital channels. In addition, advancements in e-commerce and telehealth technologies further drive the online providers' significance in the cancer supportive care drugs market, making them a dynamic and evolving aspect of the healthcare landscape.
North America is expected to maintain its dominance by 2032
Based on region, North America held the highest market share in terms of revenue in 2022, accounting for almost half of the global cancer supportive drugs market revenue, owing to several factors. The robust market position is attributed to the well-established healthcare infrastructure, high cancer incidence, advanced treatment accessibility, and a strong focus on improving patient outcomes in the region. However, the Asia-Pacific segment is projected to register the highest CAGR of 2.81% during the forecast period owing to the large population base, increase in healthcare awareness, and rise in incidences of cancer cases contributing to a growing demand for cancer supportive care drugs in this region.
For Procurement Information - https://www.alliedmarketresearch.com/purchase-enquiry/A07133
Leading Market Players:
- Novartis AG
- Johnson & Johnson
- Amgen Inc.
- Baxter International Inc.
- F. Hoffmann-la Roche AG
- Helsinn Healthcare SA
- Heron Therapeutics, Inc.
- Merck And Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
The report provides a detailed analysis of these key players in the global cancer supportive drugs market. These players have adopted different strategies such as agreement and product approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Comprehensive Healthcare Industry Research Studies: -
Bone Grafts and Substitutes Market - Opportunity Analysis and Industry Forecast, 2022–2032
Cardiac Mapping Market - Opportunity Analysis and Industry Forecast, 2022–2032
Medical Simulation Market Size - Global Opportunity Analysis and Industry Forecast, 2022–2032
Dermatologicals Market - Global Opportunity Analysis and Industry Forecast, 2022–2032
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
